GLP-1 and Vaginal Side Effects: What Women Report and What the Evidence Says

Some women on GLP-1 medications (GLP-1 receptor agonists such as semaglutide, sold as Ozempic and Wegovy; tirzepatide, sold as Mounjaro and Zepbound) report vaginal changes — dryness, irritation, discharge or itch, and shifts in their menstrual cycle. It is worth being clear up front: these are reported experiences, not effects established by good evidence, and none of them appear on the FDA adverse-reaction list for these drugs. Where a mechanism is plausible, the most likely story is rapid weight loss rather than the medicine itself. And the genital yeast infections people often search for under "Ozempic side effects" are a well-documented effect of a different class of diabetes drug — SGLT2 inhibitors — not GLP-1s. This page separates what is reported from what is known, and explains that distinction carefully. This is general information, not medical advice — talk to your prescriber about your own situation.

What women actually report

In patient forums, clinic anecdotes, and consumer health articles, women on GLP-1s describe a handful of vaginal and intimate changes. None of these are listed in the prescribing information as side effects of the drug, and most can be explained by other things going on at the same time — but they are reported often enough to be worth naming honestly:

• Vaginal dryness and irritation — a feeling of dryness, sometimes with discomfort during sex.
• Yeast- or BV-type symptoms — itching, abnormal discharge, or odor that women attribute to the medication.
• Discharge changes — more, less, or different from usual.
• Menstrual-cycle changes — periods becoming irregular, lighter or heavier, or returning after having stopped. These cluster during the phase of rapid weight loss and tend to settle as weight stabilizes.
• Sexual-function changes — isolated reports of reduced lubrication or sensation, including a single published case of anorgasmia.

You may also see figures quoted, such as dryness affecting "up to about 10%" of women on these drugs. Those numbers are not drawn from clinical trials or any cited dataset, so we treat them as illustrative of the conversation rather than as data. The honest summary is that these symptoms are reported and under-studied, not measured.

What the evidence actually shows

When you move from anecdote to evidence, the picture is thin — and what evidence exists points away from the medication being the direct cause.

The clearest source is the drug labeling. The FDA adverse-reaction list in the semaglutide (Ozempic) prescribing information contains no vaginal, genital, or yeast (mycotic) entries at all. The documented reactions are dominated by gastrointestinal effects, alongside items such as gallstones, diabetic retinopathy, pancreatitis, acute kidney injury, and low blood sugar. In other words, vaginal and genital symptoms are not an established labeled effect of this class — if they were a recognized drug reaction, this is where they would appear.

Sexual function has been looked at only at the margins. There is one published case report — a single patient who developed anorgasmia after starting a GLP-1 — and even there, the authors note explicitly that "sexual dysfunction is not a known side effect of GLP-1 agonists". A separate signal in insurance-claims data has been raised, but that kind of analysis is easily confounded by the underlying conditions these women have (more on that below) and cannot show that the drug is the cause.

Put plainly: this is under-studied territory, and there is no high-quality, GLP-1-specific evidence that the medication itself causes vaginal infections or dryness.

Why weight loss — not the molecule — is the likeliest explanation

If symptoms are real for the women reporting them, what could be driving them? The most defensible answers are hypotheses, and the strongest of them is about weight loss rather than any direct drug action:

• Lower estrogen from fat loss. Body fat produces estrogen (via an enzyme called aromatase). Rapid fat loss can lower estrogen, and low estrogen is a well-established cause of vaginal dryness — for example around menopause. This is plausibly an effect of losing weight quickly, which these drugs cause, rather than a property of the molecule itself.
• Cycle changes from an energy deficit. A large, fast calorie deficit shifts reproductive hormones, which can make periods irregular, lighter, heavier, or — if they had stopped — return. This too tracks with the pace of weight loss, which is why it tends to settle as weight stabilizes.
• Changing infection risk in diabetes — direction uncertain. For women with diabetes, better blood-sugar control could in theory change susceptibility to infections, but which way is unclear, and this would not apply to women taking the drug purely for weight loss.
• Microbiome and hygiene shifts are sometimes suggested, but this is speculative and not supported by direct evidence.

The thread running through all of these is that the plausible mechanisms are downstream of weight loss, not pharmacologic effects of the GLP-1 — and all of them remain unproven.

The important mix-up: yeast infections belong to a different drug class

This is the single most important thing to get right on this page, because the public conversation routinely gets it wrong.

Genital yeast infections are a real, labeled, well-established side effect — but of SGLT2 inhibitors, a different class of diabetes medication. That class includes canagliflozin (Invokana), dapagliflozin (Farxiga), and empagliflozin (Jardiance). These drugs work by making the kidneys spill excess sugar into the urine (glycosuria), which creates a sugar-rich environment that yeast thrives in. The effect is common enough to be on the label: the dapagliflozin (Farxiga) prescribing information lists female genital yeast infections in roughly the 5–12% range, and a pharmacovigilance review of FDA adverse-event reports found genital fungal infections strongly and specifically reported for SGLT2 inhibitors. The FDA has also warned of a rare but serious perineal infection (Fournier's gangrene) with this class.

GLP-1s do not cause glycosuria, so this mechanism — and this risk — does not transfer to them. A pharmacist-reviewed explainer makes the same point directly: yeast infections are not associated with GLP-1 drugs, and the genital-yeast risk people have heard about comes from SGLT2 inhibitors.

Why does this matter so much? Because both classes are used in type 2 diabetes, and many people search "does Ozempic cause yeast infections" having absorbed a risk that actually belongs to Farxiga or Jardiance. The two often get conflated in the public record, and that confusion is a large part of why GLP-1s have a reputation here that the evidence does not support. If you are worried about yeast infections, the relevant question is which class of drug you are on.

When to see a clinician

Whatever the cause, vaginal symptoms that are bothering you deserve attention on their own terms — not because the GLP-1 is presumed responsible, but because they are treatable and worth getting checked:

• Yeast-infection signs — itching, thick white discharge, and pain with urination or sex — especially if they keep coming back or are not improving with usual care.
• Bacterial-vaginosis signs — thin grey discharge with a fishy odor.
• Persistent dryness or pain with sex that is affecting your comfort or relationships.
• Abnormal or persistent menstrual changes, or missed periods. One evidence-backed point belongs here: weight loss can restore fertility, and getting pregnant while on a GLP-1 is not recommended — so a return of periods is a real reason to revisit contraception with your clinician. This is the actionable take-home, rather than any claim that the drug is toxic.

Most vaginal symptoms are common, benign, and easily treated, and the point of knowing the urgent signs is so you can tell the difference quickly. For where this fits among the other serious GLP-1 risks, see the hub, and for the milder, better-documented effects of these drugs, see the side effects overview.

Frequently asked questions

Do GLP-1 drugs like Ozempic cause vaginal yeast infections? There is no good evidence that they do, and yeast/genital infections are not listed in the GLP-1 (semaglutide) label at all. The genital yeast-infection risk people often hear about belongs to a different class of diabetes drug — SGLT2 inhibitors such as Farxiga and Jardiance — which cause sugar in the urine. GLP-1s do not, so that risk does not transfer to them.

Why might I feel vaginal dryness on a GLP-1, then? The most likely explanation is rapid weight loss rather than the drug itself: losing fat quickly can lower estrogen, and low estrogen is a well-known cause of vaginal dryness. This is a plausible, unproven mechanism — the symptom is reported but under-studied, so it is worth raising with your clinician, who can treat dryness regardless of the cause.

Why has my period changed since starting a GLP-1? Fast weight loss and a large calorie deficit can shift reproductive hormones, making periods irregular, lighter, heavier, or — if they had stopped — return. This tends to settle as your weight stabilizes. The key practical point is that returning periods can mean returning fertility: pregnancy on a GLP-1 is not recommended, so talk to your clinician about contraception.

How we reviewed this: written from authoritative sources, including the semaglutide (Ozempic) prescribing information, a published case report on sexual function and GLP-1 agonists, a pharmacovigilance review of genital fungal infections and SGLT2 inhibitors, and a pharmacist-reviewed explainer on GLP-1s and yeast infections. This is an under-studied topic, and much of what circulates online conflates GLP-1s with SGLT2 inhibitors or with the effects of rapid weight loss — where the evidence is thin or pointing elsewhere, we say so plainly rather than implying a drug effect the data does not support. See our editorial and review policy and sourcing standards.